J. Barben (St. Gallen, Switzerland), E. McKone (Dublin 4, Ireland)
Prospective case-control study describing the lower airway microbiome in pre-school children with cystic fibrosis
B. Linnane (Limerick, Ireland), P. Cotter (Cork, Ireland), O. O'Sullivan (Cork, Ireland), F. Crisbie (Cork, Ireland), A. Walsh (Cork, Ireland), J. Renwick (Dublin, Ireland), P. Mcnally (Dublin, Ireland)
|    |
Antibody testing for Mycobacterium avium complex infection in cystic fibrosis patients
C. Ravnholt (Copenhagen, Denmark), T. Qvist (Copenhagen, Denmark), T. Pressler (Copenhagen, Denmark), M. Kolpen (Copenhagen, Denmark), N. Høiby (Copenhagen, Denmark)
| |
Detection of Pseudomonas aeruginosa in exhaled breath of cystic fibrosis patients
A. Neerincx (Amsterdam, Netherlands), P. Brinkman (Amsterdam, Netherlands), P. Van Der Gouwe (Amsterdam, Netherlands), T. Paff (Amsterdam, Netherlands), N. Fens (Amsterdam, Netherlands), M. Gerritsen (Amsterdam, Netherlands), E. Haarman (Amsterdam, Netherlands), W. Van Aalderen (Amsterdam, Netherlands), C. Majoor (Amsterdam, Netherlands), E. Weersink (Amsterdam, Netherlands), L. Bos (Amsterdam, Netherlands), P. Sterk (Amsterdam, Netherlands), A. Maitland-Van Der Zee & The Amsterdam Cf Research Group (Amsterdam, Netherlands)
|  |
Distinct volatile markers from Cystic Fibrosis pathogens with Secondary Electrospray Ionisation High-resolution Mass Spectrometry (SESI-HRMS)
A. Baghdasaryan (Zurich, Switzerland), T. Bruderer (Zurich, Switzerland), S. Mueller (Zurich, Switzerland), R. Weber (Zurich, Switzerland), N. Haas-Baumann (Zurich, Switzerland), S. J. Micic (Zurich, Switzerland), C. Berger (Zurich, Switzerland), R. Zenobi (Zurich, Switzerland), A. Möller (Zurich, Switzerland)
| |
Randomized, double-blind, controlled trial of preventive inhalation of hypertonic saline in infants with CF (PRESIS)
M. Stahl (Heidelberg, Germany), M. Wielpuetz (Heidelberg, Germany), I. Ricklefs (Lübeck, Germany), S. Graeber (Heidelberg, Germany), O. Sommerburg (Heidelberg, Germany), G. Diekmann (Lübeck, Germany), C. Dopfer (Hannover, Germany), S. Barth (Giessen, Germany), A. Schlegtendal (Bochum, Germany), C. Koerner-Rettberg (Bochum, Germany), L. Naehrlich (Giessen, Germany), B. Tuemmler (Hannover, Germany), M. Kopp (Lübeck, Germany), M. Mall (Heidelberg, Germany)
| |
Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis
E. Bush (Madison, WI, United States of America), A. Nicholas (Madison, WI, United States of America), T. Pei (Madison, WI, United States of America), I. Kuipers (Madison, WI, United States of America), W. Cheng (Madison, WI, United States of America), H. Hamilton (Madison, WI, United States of America), J. Hegge (Madison, WI, United States of America), X. Li (Madison, WI, United States of America), A. Glebocka (Madison, WI, United States of America), R. Zhu (Madison, WI, United States of America), B. Chen (Madison, WI, United States of America), P. Kuehl (Albuquerque, NM, United States of America), T. Schluep (Madison, WI, United States of America), Z. Li (Madison, WI, United States of America)
| |